Navigation Links
Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
Date:3/31/2008

Lowering the blood pressure of elderly patients could cut their total mortality by a fifth and their rate of cardiovascular events by a third, according to a new study presented today at the American College of Cardiology in Chicago and published simultaneously in the New England Journal of Medicine.

LONDON, March 31 /PRNewswire/ -- The 3,845 patient Hypertension in the Very Elderly Trial (HYVET), which is co-ordinated by scientists from Imperial College London, is the largest ever clinical trial to look at the effects of lowering blood pressure solely in those aged 80 and over. Patients were given either a placebo or the diuretic indapamide slow release (SR) 1.5mg, with the addition of the ACE inhibitor perindopril in tablet form once a day.

The research shows that the benefits of treatment include a 21% (p=0.02) reduction in total mortality rate, a 39% (p=0.05) reduction in stroke mortality rate, a 64% (p<0.001) reduction in fatal and non-fatal heart failures and a 34% (p<0.001) reduction in cardiovascular events. The benefits were apparent within the first year of follow-up.

The reduction in overall mortality was a novel and unexpected result. Earlier trials had demonstrated that reducing blood pressure in the under-80s reduces stroke and cardiovascular events. However, previous smaller and inconclusive studies also suggested that whilst lowering blood pressure in those aged 80 or over reduced the number of strokes, it did not reduce, and even possibly increased, total mortality.

In July 2007 the trial was stopped early on the recommendation of an independent data monitoring committee after they observed significant reductions in overall mortality and stroke in those receiving treatment. The final results of the trial showed a significant reduction in stroke mortality rate, but the reduction in all strokes of 30% did not quite reach statistical significance (p=0.06). In those aged 80 and over, up to half of strokes are fatal and
'/>"/>

SOURCE Imperial College London
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
2. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
3. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
4. InterMune to Present at the SIGnificant Options in Healthcare Conference
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
7. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
10. Significant Progress Made in Nations Preparedness to Respond to Public Health Emergencies; But Gaps in Critical Areas Threaten Overall Readiness
11. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014  ( www.competitivehealth.com ... CoPatient, an online medical bill review and advocacy service, ... in the FREE WellCard Savings discount health services marketplace. ... bill that was more than they expected to pay. ... reduce health care costs, WellCard Savings is pleased to ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... PALO ALTO, Calif., Feb. 20 CV Therapeutics, Inc. ... board of directors has thoroughly reviewed and rejected the ... acquire CV Therapeutics at a price of $16.00 per ... its independent financial and legal advisors, the CV Therapeutics ...
... Nyenrode Business,Universiteit has awarded a Honorary Doctoral degree ... microeconomics, competitive strategy and cluster,theory. Professor Porter is ... of strategy and the world,s most influential thought ... Professor Porter will receive,the Honorary Doctorate on Wednesday ...
... $0.90 to $1.10 for 2009 and $1.50 to $1.70 for 2010PITTSBURGH, ... announced its financial results for the three and twelve months ended ... to $1.10 for 2009 and $1.50 to $1.70 for 2010. , ... Adjusted diluted EPS of $0.26 and $0.80 ...
Cached Biology Technology:CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 2CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 3CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 4Nyenrode Honorary Doctorate for Professor Michael E. Porter 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 3Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 4Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 5Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 6Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 7Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 8Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 9Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 10Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 11Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 12Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 13Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 14Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 15Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 16Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 17
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... to be particularly prone to global warming caused by ... greenhouse gases. Now, a University of Utah study finds ... north: the Arctic's well-known haze ?made of particulate pollution ... better able to trap heat. , The effect makes ...
... dioxide from fossil fuel burning are dramatically altering ... that secrete skeletal structures and support oceanic biodiversity. ... effects of increased atmospheric carbon dioxide on these ... research for determining the extent of the impacts. ...
... stem cells, prized for their astonishing ability to apparently transform ... identities in part by interacting with their surroundings - even ... dish, University of Florida scientists report. , Using an animal ... Brain Institute have begun to answer one of the most ...
Cached Biology News:Pollutant haze heats the Arctic 2Pollutant haze heats the Arctic 3Pollutant haze heats the Arctic 4Report warns about carbon dioxide threats to marine life 2Report warns about carbon dioxide threats to marine life 3Medium is the message for stem cells in search of identities 2Medium is the message for stem cells in search of identities 3
... ImmEdge Pen, a hydrophobic barrier pen for ... for use with frozen or paraffin-embedded tissue ... Pen provides a heat-stable, water-repellent barrier that ... sections, prevents mixing of reagents when differentially ...
... Covance's BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... purple staining with minimal background ...
... CellBIND surface is produced by a patented ... surface giving more consistent, even cell attachment, ... cell attachment and growth uunder difficult conditions, ... CellBIND may provide a more ecominic alternative ...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Biology Products: